BOSTON: The U.S. Food and Drug Administration has granted approval for only five drugs to treat the symptoms of Alzheimer’s disease.
Broomfield-based Accera Inc. wants to develop the sixth and this week named a new CEO to lead the charge.
Dr. Charles Stacey, a former surgeon and neuroscience researcher, has been named president and CEO of the privately held firm.
Stacey’s appointment headlines a shift in management and strategy for Accera, which previously gained mixed reaction — and, eventually, an FDA warning letter — for its Axona “milkshake,” a medical food to improve cognitive functions in patients suffering from mild to moderate symptoms of Alzheimer’s. Accera now is focused exclusively on advancing a new therapy, AC-1204, through the regulatory process, Stacey said. Accera currently is enrolling for late-stage clinical trials related to AC-1204…